Abstract
Aggregation of amyloid-β (Aβ) protein plays a central role in Alzheimer's disease. Because protein aggregation is a concentration-dependent process, rigorous investigations require accurate concentration measurements. Owing to the high aggregation propensity of Aβ protein, working solutions of Aβ are typically in the low micromolar range. Therefore, an ideal Aβ quantification method requires high sensitivity without sacrificing speed and accuracy. Absorbance at 280 nm is frequently used to measure Aβ concentration, but the sensitivity is low with only one tyrosine and no tryptophan residues in the Aβ sequence. Here we present a fluorescence method for Aβ quantification using fluorescamine, which gives high fluorescence upon reaction with primary amines. We show that, using hen egg white lysozyme as a standard, fluorescence correlates linearly with primary amine concentration across a wide range of fluorescamine concentrations, from 62.5 to 1000 µM. The maximal sensitivity of detection is achieved at a fluorescamine concentration of 250 µM or higher. The fluorescamine method is compatible with the presence of dimethyl sulfoxide, which is commonly used in the preparation of Aβ oligomers, and limits the use of absorbance at 280 nm due to its high background reading. Using aggregation kinetics, we show that the fluorescamine method gives accurate concentration measurements at low micromolar range and leads to highly consistent aggregation data. We recommend the fluorescamine assay to be used for routine and on-the-fly concentration determination in Aβ oligomerization and fibrillization experiments.
Keywords: fluorescamine, Alzheimer's disease, amyloid, Aβ40, Aβ42, protein aggregation
1. Introduction
The aggregation of amyloid-β (Aβ) protein leads to the formation of a wide range of aggregates, from soluble oligomers to insoluble fibrils [1]. These Aβ aggregates play a central role in the pathogenesis of Alzheimer's disease [2]. Because protein aggregation is a concentration-dependent process, quantitative analysis of Aβ aggregation and rigorous studies of the bioactivity of these Aβ aggregates would require accurate measurement of Aβ concentration. Two characteristics of the Aβ protein restrict the use of otherwise commonly employed protein quantification methods. The first characteristic is its high aggregation propensity. Aβ42 aggregation typically occurs within hours at 37°C [3,4]. This leads to the second characteristic of Aβ protein, that working solutions of Aβ are typically in the low micromolar range. In order to acquire the concentration of an Aβ42 sample in its pre-fibrillar state, the quantification method must be fast and sensitive. A commonly used protein quantification method is absorbance at 280 nm. Because Aβ42 has only one tyrosine and no tryptophan residues, the extinction coefficient at 280 nm is very low, at 1280 M−1 cm−1 [5]. To achieve an absorbance reading of 0.1 at 280 nm, the concentration of Aβ needs to be approximately 80 µM. Working solutions of Aβ42 are rarely that high in concentration, and typical concentrations for Aβ42 aggregation experiments (less than 50 µM) fall well below the sensitive range of UV absorbance [6,7]. Use of dimethyl sulfoxide (DMSO) as a solubilizing reagent for some Aβ protocols (e.g. Aβ-derived diffusible ligands, or ADDLs) [8] further limits the use of absorbance due to the high background signal of DMSO.
Likely due to the lack of fast and sensitive quantification methods for Aβ, many Aβ studies have relied on ‘nominal' concentrations without actually measuring them. For example, several studies [9–12] on ADDLs rely on the accurate quantity of starting Aβ material, often provided by the vendor, and no Aβ quantifications were performed to verify the concentration. Biochemical and biophysical characterization of these Aβ oligomers reveals large variations in their characteristics, from morphology to size. Freir et al. [11] reported ADDLs that are rich in elongated structures, while Laurén et al. [10] reported ADDLs that are dominantly globular. Studies by both Freir et al. [11] and Laurén et al. [10] show that ADDLs are large on the scale of hundreds of kilodaltons, but studies by the William Klein laboratory, the group that discovered these oligomers, show that active ADDLs have sizes of 10–100 kDa [13]. Accurate Aβ quantification may not completely resolve the inconsistencies from one laboratory to another, but it will certainly be a concrete first step to improve data reproducibility in Aβ research.
Here we propose to use a fluorescamine assay as a routine and on-the-fly method for Aβ quantification. Fluorescamine is a non-fluorescent compound that reacts with primary amines to produce highly fluorescent products [14]. Since its introduction by Udenfriend et al. [14] in 1972, several studies [15–20] have investigated the mechanism and optimization of fluorescamine assays. However, the fluorescamine method has never become a routine technique for protein quantification. Compared with other commonly used protein quantification methods such as Lowry [21], Bradford [22] and BCA [23], the major advantage of the fluorescamine method is that it does not require incubation and thus is truly a mix-and-click method. The only limitations of the fluorescamine method are that it relies on the knowledge of the number of accessible lysines in the protein and that the buffer cannot contain any primary amines (ruling out the use of glycine or Tris). In the particular case of Aβ, these conditions are usually satisfied as Aβ experiments are generally performed with purified Aβ in PBS buffer. Here, we show that fluorescamine is an ideal reagent for the quantification of low concentrations of Aβ proteins, in that the method is both fast and highly sensitive. We show that hen egg white lysozyme, with its primary amines readily accessible [24], is a suitable protein standard for the fluorescamine method. We explore a range of concentrations of fluorescamine for the quantification of Aβ, and finally, we show that highly consistent Aβ aggregation kinetics can be obtained when Aβ concentration is determined using the fluorescamine method.
2. Results and discussion
2.1. Choice of lysozyme as the protein standard for the fluorescamine method
Lysozyme is a commercially available protein standard. It is extremely stable, with a melting temperature of 74°C at neutral pH [25]. Most importantly, lysozyme contains seven primary amine groups, all of which can be readily modified [24]. This property makes lysozyme an ideal standard for protein quantification using fluorescamine, whose fluorescence depends on reaction with primary amine groups. By contrast, bovine serum albumin (BSA), a more commonly used standard for protein quantification, has 60 primary amine groups, and 20 of these amines are buried and cannot be readily labelled [26]. Variations in the extent of fluorescamine modification in albumin would lead to large measurement errors in protein quantification. Therefore, even though BSA has been used as a standard for fluorescamine assays in the literature [27], we consider it not an ideal standard for this particular application.
2.2. Standard curves and Aβ concentration measurements at different fluorescamine concentrations
Previous fluorescamine methods of protein quantification have used a wide range of fluorescamine concentrations, including 90 µM [14], 120 µM [19], 216 µM [20], 250 µM [15,16], 360 µM [18], 1.6 mM [28] and 2.2 mM [27]. To examine the precision of protein quantification using various fluorescamine concentrations, and to see if there exists a fluorescamine concentration with the greatest sensitivity of detection, we tested five fluorescamine concentrations at 62.5, 125, 250, 500, 1000 µM and obtained standard curves using hen egg white lysozyme (figure 1). At all fluorescamine concentrations, a linear relationship was found for lysozyme concentrations in the range of 0.1–2 µM, corresponding to amine concentrations of 0.7–14 µM. For comparison, we obtained a BSA standard curve at 500 µM of fluorescamine (figure 1d). When plotted as a function of amine concentrations, the BSA standard gives a lower slope than the lysozyme data, due to the presence of buried lysines in BSA [26].
In all the standard curves with lysozyme, the lowest lysozyme concentration was 0.1 µM, and this corresponds to an amine concentration of 0.7 µM. Because Aβ consists of three primary amines, the 0.7 µM amine concentration can be translated into 0.23 µM Aβ concentration. Therefore, these standard curves suggest that the fluorescamine method may be able to detect Aβ at as low as 0.23 µM. The detection sensitivity of the fluorescamine method is further investigated below.
To establish a comparison between concentration measurements using fluorescamine and absorbance at 280 nm, we determined the concentration of Aβ40 using both methods (figure 2). For this purpose, we compared two tubes of Aβ40 powder with equal weight. One tube of Aβ40 was dissolved in a high pH denaturing buffer containing 20 mM CAPS (pH 11) and 7 M guanidine hydrochloride (GdnHCl). The absorbance at 280 nm was measured without further dilution to achieve a reading between 0.5 and 1.0. Then the concentration was calculated using an extinction coefficient of 1280 M−1 cm−1 [5]. For the fluorescamine method, the other tube of Aβ40 was dissolved in one volume of 10 mM NaOH, followed by addition of eight volumes of PBS and one volume of 10 mM HCl. The Aβ40 sample was diluted with PBS so that a fluorescence reading in the middle of the standard curve could be obtained, corresponding to an Aβ40 concentration of approximately 2 µM. Aβ40 concentration was determined using different fluorescamine concentrations (62.5, 125, 250, 500 and 1000 µM), and the results are shown in figure 2. In general, the measured Aβ40 concentrations using the five fluorescamine concentrations are in good agreement with the concentration determined using UV absorbance. For reasons we do not fully understand, the measured Aβ concentrations obtained using the low fluorescamine concentrations (62.5 and 125 µM) are higher than that obtained using absorbance, while the high fluorescamine concentrations (250, 500 and 1000 µM) yielded lower concentrations than the absorbance method (figure 2). It is also worth pointing out that the measured Aβ concentrations using high fluorescamine concentrations (greater than 250 µM) have better agreement with the absorbance method.
2.3. Fluorescamine method is compatible with high concentrations of dimethyl sulfoxide and hexafluoroisopropanol
Preparation of Aβ oligomers, such as ADDLs [29], often involves solubilizing Aβ in DMSO. Owing to its high absorbance at 280 nm, the presence of DMSO may not allow for reliable concentration measurements using UV absorbance. Here we investigated whether DMSO is compatible with the fluorescamine method. Figure 3a shows the standard curve in the presence of 70% DMSO. The linear relationship remains, with an r2 value at greater than 0.99, but the slope with 70% DMSO is dramatically lower than the slope without DMSO. Additional fluorescamine measurements with lower concentrations of DMSO show that the slope of the standard curve increases with decreasing concentrations of DMSO (data not shown). Therefore, it is important that, for accurate concentration measurements, the standard curves should be obtained according to the buffer compositions of the specific experiments.
Similar to DMSO, hexafluoroisopropanol (HFIP) and trifluoroacetic acid (TFA) are two organic solvents that are commonly used to solubilize and disaggregate Aβ. Here we also examined if the fluorescamine method is compatible with HFIP and TFA. We found that a linear relationship exists between fluorescamine fluorescence and lysozyme concentration in the presence of 70% HFIP (figure 3a). However, the presence of 70% TFA completely abolished the fluorescamine reaction (figure 3a).
Consequent concentration determination of the Aβ42 sample demonstrates good agreement between the measurements in the absence of any organic solvents and in the presence of 70% DMSO or 70% HFIP (figure 3b). However, the slope of the standard curve is lower with 70% DMSO or 70% HFIP, indicating that sensitivity may be lower. DMSO also gives a higher background signal in the absence of proteins. Because HFIP is a volatile solvent, extra care must be taken when performing assays with HFIP, which evaporates quickly and may contribute to larger errors in concentration measurements (figure 3b).
2.4. Optimal fluorescamine concentrations for maximal sensitivity
We assessed the effect of fluorescamine concentration on the sensitivity of protein quantification using the standard curves. Such sensitivity is related to both the slope of the standard curve and the background fluorescence. A steeper standard curve (with a larger slope) corresponds to higher sensitivity toward changes in protein concentration. As shown in figure 4a, the slope of the standard curve increases with increasing fluorescamine concentrations from 62.5 µM to 250 µM, and approaches plateau above 250 µM. Background noise must also be considered a factor in analysing sensitivity, because fluorescamine gives a low but evident fluorescence signal in the absence of proteins. Because of this, background noise can take up a significant portion of overall fluorescence intensity when protein concentration is low. As shown in figure 4b, the background noise increases with increasing concentrations of fluorescamine from 62.5 µM to 250 µM, approaching plateau above 250 µM. Therefore, we use a ratio of slope to background noise as a measure of sensitivity, as shown in figure 4c. Maximum sensitivity is reached at 250 µM fluorescamine and plateaus thereafter.
We also compared the Aβ detection sensitivity of the fluorescamine method and absorbance method (figure 5). For the fluorescamine method, we started from an Aβ42 sample in PBS at 1 µM concentration, which was determined using fluorescamine. Then this Aβ42 sample was diluted to 0.8, 0.6, 0.5 0.4, 0.3, 0.2, 0.1 and 0.05 µM, and the concentration was determined using fluorescamine. As shown in figure 5a, we found perfect agreement between measured concentrations and calculated concentrations when Aβ concentration is 0.5 µM or higher. Aβ concentrations at 0.4, 0.3 and 0.2 µM showed a difference of 7%, 19% and 32% between measured and calculated values. At concentrations of 0.1 µM or lower, the signal is not significantly higher than background.
For the absorbance method, we started from an Aβ42 sample dissolved in a high pH denaturing buffer containing 20 mM CAPS (pH 11) and 7 M GdnHCl at a concentration of 350 µM, which was determined using absorbance at 280 nm. We then diluted this Aβ sample to 200, 100, 50, 20 and 10 µM, and the concentration was determined again using absorbance. As shown in figure 5b, we found perfect agreement when Aβ concentration is 50 µM or higher. However, a deviation of 44% from the calculated value was found for the 20 µM Aβ42 sample, and a deviation of greater than 100% from the calculated value was found for the 10 µM Aβ42 sample, suggesting that absorbance at 280 nm is not suitable for Aβ concentrations at 20 µM or lower. At 20 µM, the theoretical absorbance value of Aβ is approximately 0.023, a value that is generally considered too low for accurate measurement of absorbance.
2.5. Evaluation of fluorescamine method using aggregation kinetics
Eventually, the real test of the rigour of a quantification method is how it performs in experimental applications. Most in vitro Aβ aggregation experiments involve the preparation of oligomers and fibrils, or the study of aggregation kinetics. Here we use aggregation kinetics to evaluate the accuracy of the fluorescamine method in determining Aβ concentration.
We prepared three independent Aβ42 samples in PBS buffer at concentrations of 30–40 µM, as determined by absorbance at 280 nm. Aβ42 concentrations at this range ensure relatively accurate concentration measurements using absorbance. The concentration of each sample was also determined using fluorescamine. Then we set up aggregation kinetics experiments at 5 µM concentration, with four repeats for each sample. The results, as shown in figure 6, show that similar aggregation kinetics curves were obtained with concentrations determined with fluorescamine (figure 6a) and absorbance (figure 6b). The two sets of experiments have similar lag time and similar fluorescence intensity at aggregation plateau, which is a quantitative measure of the amount of amyloid fibrils [3]. Therefore, these results show a general agreement between the fluorescamine and absorbance methods. However, the kinetics curves with the fluorescamine method are more tightly clustered together than those with the absorbance method (figure 6c), suggesting that the fluorescamine method has better consistency for low Aβ concentrations.
We next investigated whether fluorescamine can be used to monitor the Aβ concentration during the process of aggregation. If lysine residues were exposed in the fibrils, we would be able to determine Aβ concentration for not just soluble Aβ, but also aggregated Aβ. As shown in figure 7a, upon incubation at 37°C for 24 h, the apparent Aβ42 concentration as determined using fluorescamine fluorescence was reduced by approximately 70%, suggesting that the majority of the lysine residues became buried in the fibrils. By contrast, incubation of Aβ42 samples at 4°C results in only small changes in apparent concentration for at least 48 h (figure 7b), suggesting that Aβ42 samples remain soluble at 4°C during the incubation period.
3. Conclusion
Absorbance at 280 nm has proven to be a fast and reliable way to quantify proteins, but its sensitivity is low. In Aβ aggregation experiments, especially for Aβ42, protein concentration must be kept in the low micromolar range to prevent rapid fibrillization, and more sensitive protein quantification methods are required. Here we present a fluorescamine method for quantification of Aβ in vitro. We show that fluorescamine fluorescence correlates linearly with lysozyme concentration with sub-micromolar sensitivity. Concentration measurements with fluorescamine can be performed in the presence of DMSO, making fluorescamine an ideal reagent for Aβ oligomer preparations where DMSO is often a required solvent. Using fluorescamine, highly consistent aggregation kinetics can be obtained. To facilitate reproducibility in Aβ studies, we recommend the fluorescamine method to be used for routine and on-the-fly Aβ quantification for a wide range of Aβ experimental applications.
4. Material and methods
4.1. Preparation of Aβ proteins
Aβ was prepared as previously described [3,4,30]. Briefly, Aβ protein was expressed in Escherichia coli as a fusion protein, GroES-ubiquitin-Aβ. After purification, the fusion protein was cleaved to obtain full-length Aβ without any extra residues. Finally, Aβ was lyophilized and stored at −80°C.
4.2. Standard curves for the fluorescamine method
A stock solution of 50 mM fluorescamine (Acros Organics, pure grade) was made by adding acetonitrile to the glass bottle shipped from the manufacturer. The concentration of fluorescamine was calculated based on the weight (supplied by the manufacturer). Other concentrations of fluorescamine stock were then diluted using acetonitrile. A stock solution of 50 µM hen egg white lysozyme (Fisher Bioreagents, crystalline powder) was made in deionized water, and the concentration was determined using absorbance at 280 nm and an extinction coefficient of 38 000 M−1 cm−1 [31]. Other concentrations of lysozyme stock were then diluted using deionized water. Solutions of BSA were diluted from 2 mg ml−1 Albumin Standard Ampules (Thermo Scientific Pierce) using deionized water.
Standard curves were prepared using stock concentrations of hen egg white lysozyme and fluorescamine. First, 5 µl of lysozyme stock solutions at concentrations of 1, 2, 4, 6, 8, 10, 12, 15 and 20 µM were mixed with 40 µl of PBS buffer (50 mM phosphate, 140 mM NaCl, pH 7.4). The blank is a mixture of 5 µl of deionized water and 40 µl of PBS buffer. Second, 5 µl of fluorescamine stock solution at concentrations of 0.625, 1.25, 2.5, 5 and 10 mM were pipetted in and immediately mixed by stirring with the pipetting tip. We found that vortexing gave higher background noise readings and should be avoided. Amine concentrations were calculated by multiplying lysozyme concentrations by 7 (as each lysozyme protein contains seven primary amine groups). Standard curves with BSA were also prepared using 500 µM fluorescamine and the concentration of BSA was converted to amine concentration by multiplying by 60 (as each BSA contains 60 primary amine groups).
Standard curves with 70% DMSO, 70% HFIP or 70% TFA were prepared similarly as the above except 35 µl of DMSO, HFIP or TFA were used to substitute 35 µl of PBS buffer.
After addition of fluorescamine, all samples were immediately transferred to a black 384-well Nonbinding Surface microplate with clear bottom (Corning product no. 3655). Fluorescence readings were measured at room temperature using a Spectramax Gemini EM plate reader (Molecular Devices), with excitation at 390 nm and emission at 478 nm. Least-squares regression analyses on the standard plots were performed using SigmaPlot (Systat Software, Inc).
4.3. Concentration measurements of Aβ40 using fluorescamine and absorbance
One tube of Aβ40 powder (approx. 200 µg) was dissolved in 500 µl of HFIP, split into two tubes, and dried with a gentle stream of argon gas. For the absorbance method, one tube of Aβ40 was then dissolved in CG buffer (20 mM CAPS, 7 M GdnHCl, pH 11). The volume of CG buffer was chosen so that the absorbance reading would be between 0.5 and 1.0. The sample was used for absorbance measurement without further dilution. Absorbance at 280 nm was measured using a quartz microcuvette with 1 cm path length on a Jasco V-630 spectrophotometer. Concentration was calculated using an extinction coefficient of 1280 M−1 cm−1 [5]. The other tube of Aβ40 was dissolved in one volume of 10 mM NaOH. Then eight volumes of PBS were added, followed by one volume of 10 mM HCl for neutralization. To measure concentration using fluorescamine, 5 µl of Aβ40 sample was mixed with 40 µl of PBS and 5 µl of fluorescamine stock solutions. The sample was further diluted if needed so that fluorescence intensity readings would fall in the middle of the standard curves. For the fluorescamine method with DMSO or HFIP, 35 µl of DMSO or HFIP were used to substitute 35 µl of PBS buffer. Fluorescence measurements were performed the same way as the standard curves. Concentration was determined using the five different fluorescamine concentrations, with the standard curves that were established above.
4.4. Aβ42 fibrillization kinetics
Three tubes of HFIP-treated Aβ42 powder were dissolved in 1 ml of CG buffer for each tube, and buffer-exchanged to PBS using a 5 ml HiTrap desalting column (GE healthcare). The concentration of Aβ42 was determined using both absorbance and fluorescamine. Aβ42 was then diluted to 5 µM in PBS buffer containing 20 µM thioflavin T, and 50 µl of aggregation sample was transferred to a black 384-well Nonbinding Surface microplate with clear bottom (Corning product no. 3655), and sealed with a polyester-based sealing film (Corning product no. PCR-SP). Four repeats of aggregation experiments were performed for each sample. The fluorescence was measured through the bottom of the microplate with an excitation filter of 450 nm and an emission filter of 490 nm using a Victor 3 V plate reader (Perkin Elmer). The aggregation was started by putting the microplate in the reader and starting incubation at 37°C without agitation.
Acknowledgement
We thank Frederick Hsu, Hongsu Wang, Austin Hoang and James Zhen at the University of California, Los Angeles, for help with protein purification.
Data accessibility
Data available from the Dryad Digital Repository: http://dx.doi.org/10.5061/dryad.7mg3h [32].
Authors' contributions
C.X. designed and carried out experiments, analysed data and drafted the manuscript. Y.K.L., J.T. and D.C. carried out experiments and revised the manuscript. Z.G. conceived and supervised the study, designed the experiments and drafted the manuscript. All authors gave final approval for publication.
Competing interests
The authors declare no competing interests.
Funding
This work was supported by the National Institute of Health (grant no. R01GM110448).
References
- 1.Thal DR, Walter J, Saido TC, Fändrich M. 2015. Neuropathology and biochemistry of Aβ and its aggregates in Alzheimer's disease. Acta Neuropathol. 129, 167–182. (doi:10.1007/s00401-014-1375-y) [DOI] [PubMed] [Google Scholar]
- 2.Selkoe DJ, Hardy J. 2016. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol. Med. 8, 595–608. (doi:10.15252/emmm.201606210) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Xue C, Lin TY, Chang D, Guo Z. 2017. Thioflavin T as an amyloid dye: fibril quantification, optimal concentration and effect on aggregation. R. Soc. open sci. 4, 160696 (doi:10.1098/rsos.160696) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Tran J, Chang D, Hsu F, Wang H, Guo Z. 2017. Cross-seeding between Aβ40 and Aβ42 in Alzheimer's disease. FEBS Lett. 591, 177–185. (doi:10.1002/1873-3468.12526) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Edelhoch H. 1967. Spectroscopic determination of tryptophan and tyrosine in proteins. Biochemistry 6, 1948–1954. (doi:10.1021/bi00859a010) [DOI] [PubMed] [Google Scholar]
- 6.Elbassal EA, Liu H, Morris C, Wojcikiewicz EP, Du D. 2016. Effects of charged cholesterol derivatives on Aβ40 amyloid formation. J. Phys. Chem. B 120, 59–68. (doi:10.1021/acs.jpcb.5b09557) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Pauwels K, et al. 2012. Structural basis for increased toxicity of pathological Aβ42:Aβ40 ratios in Alzheimer disease. J. Biol. Chem. 287, 5650–5660. (doi:10.1074/jbc.M111.264473) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Chromy BA, et al. 2003. Self-assembly of Aβ1-42 into globular neurotoxins. Biochemistry 42, 12 749–12 760. (doi:10.1021/bi030029q) [DOI] [PubMed] [Google Scholar]
- 9.Balducci C, et al. 2010. Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein. Proc. Natl Acad. Sci. USA 107, 2295–2300. (doi:10.1073/pnas.0911829107) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Laurén J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM. 2009. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers. Nature 457, 1128–1132. (doi:10.1038/nature07761) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Freir DB, et al. 2011. Interaction between prion protein and toxic amyloid β assemblies can be therapeutically targeted at multiple sites. Nat. Commun. 2, 336 (doi:10.1038/ncomms1341) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Sinnen BL, Bowen AB, Gibson ES, Kennedy MJ. 2016. Local and use-dependent effects of β-amyloid oligomers on NMDA receptor function revealed by optical quantal analysis. J. Neurosci. 36, 11 532–11 543. (doi:10.1523/JNEUROSCI.1603-16.2016) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Lacor PN, et al. 2004. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J. Neurosci. 24, 10 191–10 200. (doi:10.1523/JNEUROSCI.3432-04.2004) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Udenfriend S, Stein S, Böhlen P, Dairman W, Leimgruber W, Weigele M. 1972. Fluorescamine: a reagent for assay of amino acids, peptides, proteins, and primary amines in the picomole range. Science 178, 871–872. (doi:10.1126/science.178.4063.871) [DOI] [PubMed] [Google Scholar]
- 15.Stein S, Böhlen P, Udenfriend S. 1974. Studies on the kinetics of reaction and hydrolysis of fluorescamine. Arch. Biochem. Biophys. 163, 400–403. (doi:10.1016/0003-9861(74)90491-3) [DOI] [PubMed] [Google Scholar]
- 16.De Bernardo S, Weigele M, Toome V, Manhart K, Leimgruber W, Böhlen P, Stein S, Udenfriend S. 1974. Studies on the reaction of fluorescamine with primary amines. Arch. Biochem. Biophys. 163, 390–399. (doi:10.1016/0003-9861(74)90490-1) [DOI] [PubMed] [Google Scholar]
- 17.Klein B, Standaert F. 1976. Fluorometry of plasma amino nitrogen, with use of fluorescamine. Clin. Chem. 22, 413–416. [PubMed] [Google Scholar]
- 18.Castell JV, Cervera M, Marco R. 1979. A convenient micromethod for the assay of primary amines and proteins with fluorescamine. A reexamination of the conditions of reaction. Anal. Biochem. 99, 379–391. (doi:10.1016/S0003-2697(79)80022-6) [DOI] [PubMed] [Google Scholar]
- 19.Bode J. 1979. On the reactions of fluorescamine with chromosomal proteins. Anal. Biochem. 99, 274–280. (doi:10.1016/S0003-2697(79)80006-8) [DOI] [PubMed] [Google Scholar]
- 20.Lorenzen A, Kennedy SW. 1993. A fluorescence-based protein assay for use with a microplate reader. Anal. Biochem. 214, 346–348. (doi:10.1006/abio.1993.1504) [DOI] [PubMed] [Google Scholar]
- 21.Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265–275. [PubMed] [Google Scholar]
- 22.Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248–254. (doi:10.1016/0003-2697(76)90527-3) [DOI] [PubMed] [Google Scholar]
- 23.Smith PK, et al. 1985. Measurement of protein using bicinchoninic acid. Anal. Biochem. 150, 76–85. (doi:10.1016/0003-2697(85)90442-7) [DOI] [PubMed] [Google Scholar]
- 24.Morshedi D, Ebrahim-Habibi A, Moosavi-Movahedi AA, Nemat-Gorgani M. 2010. Chemical modification of lysine residues in lysozyme may dramatically influence its amyloid fibrillation. Biochim. Biophys. Acta 1804, 714–722. (doi:10.1016/j.bbapap.2009.11.012) [DOI] [PubMed] [Google Scholar]
- 25.Shih P, Holland DR, Kirsch JF. 1995. Thermal stability determinants of chicken egg-white lysozyme core mutants: hydrophobicity, packing volume, and conserved buried water molecules. Protein Sci. 4, 2050–2062. (doi:10.1002/pro.5560041010) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Mir MM, Fazili KM, Abul Qasim M. 1992. Chemical modification of buried lysine residues of bovine serum albumin and its influence on protein conformation and bilirubin binding. Biochim. Biophys. Acta 1119, 261–267. (doi:10.1016/0167-4838(92)90212-V) [DOI] [PubMed] [Google Scholar]
- 27.Noble JE, Knight AE, Reason AJ, Matola AD, Bailey MJA. 2007. A comparison of protein quantitation assays for biopharmaceutical applications. Mol. Biotechnol. 37, 99–111. (doi:10.1007/s12033-007-0038-9) [DOI] [PubMed] [Google Scholar]
- 28.Bantan-Polak T, Kassai M, Grant KB. 2001. A comparison of fluorescamine and naphthalene-2,3-dicarboxaldehyde fluorogenic reagents for microplate-based detection of amino acids. Anal. Biochem. 297, 128–136. (doi:10.1006/abio.2001.5338) [DOI] [PubMed] [Google Scholar]
- 29.Lambert MP, et al. 2001. Vaccination with soluble Aβ oligomers generates toxicity-neutralizing antibodies. J. Neurochem. 79, 595–605. (doi:10.1046/j.1471-4159.2001.00592.x) [DOI] [PubMed] [Google Scholar]
- 30.Gu L, Liu C, Guo Z. 2013. Structural insights into Aβ42 oligomers using site-directed spin labeling. J. Biol. Chem. 288, 18 673–18 683. (doi:10.1074/jbc.M113.457739) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Gill SC, von Hippel PH. 1989. Calculation of protein extinction coefficients from amino acid sequence data. Anal. Biochem. 182, 319–326. (doi:10.1016/0003-2697(89)90602-7) [DOI] [PubMed] [Google Scholar]
- 32.Xue C, Lee YK, Tran J, Chang D, Guo Z. 2017. Data from: A mix-and-click method to measure amyloid-β concentration with sub-micromolar sensitivity. Dryad Digital Repository. (http://dx.doi.org/10.5061/dryad.7mg3h) [DOI] [PMC free article] [PubMed]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Citations
- Xue C, Lee YK, Tran J, Chang D, Guo Z. 2017. Data from: A mix-and-click method to measure amyloid-β concentration with sub-micromolar sensitivity. Dryad Digital Repository. (http://dx.doi.org/10.5061/dryad.7mg3h) [DOI] [PMC free article] [PubMed]
Data Availability Statement
Data available from the Dryad Digital Repository: http://dx.doi.org/10.5061/dryad.7mg3h [32].